Article
A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.
Chinese clinical oncology - 1 Dec 2016
Hirano Satoshi, Naka Go, Takeda Yuichiro, Iikura Motoyasu, Hayama Noriko, Yanagisawa Asako, Amano Hiroyuki, Nakamura Makoto, Nakamura Sukeyuki, Tabeta Hiroshi, Sugiyama Haruhito
Abstract excerpt
BACKGROUND: Maintenance therapy with full-dose erlotinib for patients with advanced non-small cell lung cancer (NSCLC) has demonstrated a significant overall survival (OS) benefit. However, 150 mg/day of erlotinib seems too toxic as maintenance therapy. This study aimed to evaluate the efficacy and safety of low-dose erlotinib (25 mg/day) as maintenance treatment after platinum doublet chemotherapy in NSCLC...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.